论文部分内容阅读
目的:探讨应用伊立替康联合顺铂治疗复发卵巢癌的临床疗效及安全性。方法:选取2009年9月～2011年9月间我院收治的复发卵巢癌患者72例作为研究对象,将其随机分为对照组(34例)和观察组(38例),对34例对照组患者单独使用伊立替康进行治疗,对38例观察组患者应用伊立替康联合顺铂进行治疗。经过一段时间的治疗,将两组患者的临床疗效及不良反应发生情况进行对比,并将对比结果及两组患者的临床资料进行回顾性的分析。结果:对照组患者的治疗总有效率为29.41%,观察组患者的治疗总有效率为57.89%,观察组患者的治疗总有效率明显高于对照组患者,差异显著(p<0.05),具有统计学意义。观察组患者出现的不良反应主要表现为较重的恶心、呕吐等症状,对照组患者出现的不良反应主要表现为轻度的恶心、呕吐等症状,观察组患者出现不良反应的严重程度及不良反应的发生率均明显高于对照组患者,差异显著(p<0.05),具有统计学意义。结论:应用伊立替康联合顺铂治疗复发卵巢癌的临床疗效显著。此疗法不仅能更好地抑制肿瘤细胞的生长,还能延长患者的生命,值得在临床上推广应用。
Objective: To investigate the clinical efficacy and safety of irinotecan combined with cisplatin in the treatment of recurrent ovarian cancer. Methods: Seventy-two patients with recurrent ovarian cancer who were admitted to our hospital from September 2009 to September 2011 were selected as the research object. They were randomly divided into control group (34 cases) and observation group (38 cases), 34 cases of control The patients were treated with irinotecan alone and 38 patients in the observation group were treated with irinotecan plus cisplatin. After a period of treatment, the two groups of patients with clinical efficacy and adverse reactions were compared, and the results of the two groups of patients and clinical data were retrospectively analyzed. Results: The total effective rate was 29.41% in the control group and 57.89% in the observation group. The total effective rate in the observation group was significantly higher than that in the control group (p <0.05) Statistical significance. Adverse reactions in the observation group were mainly severe nausea and vomiting. The adverse reactions in the control group were mainly mild nausea and vomiting. The severity of adverse reactions and adverse reactions in the observation group The incidence was significantly higher than the control group patients, the difference was significant (p <0.05), with statistical significance. Conclusion: The clinical efficacy of irinotecan plus cisplatin in the treatment of recurrent ovarian cancer is significant. This therapy can not only better inhibit the growth of tumor cells, but also prolong the life of patients, it is worth to promote the clinical application.